-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 R9Xri0pP8ER5lKm4Ta+NS6+rm94VPzD/PsXBzMDEtrnElMLscXO1Jp9FyeFohyyr
 kaqj4gT2Bss5GXm9DvzPxw==

<SEC-DOCUMENT>0001035704-04-000556.txt : 20040922
<SEC-HEADER>0001035704-04-000556.hdr.sgml : 20040922
<ACCEPTANCE-DATETIME>20040922151854
ACCESSION NUMBER:		0001035704-04-000556
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20040922
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20040922
DATE AS OF CHANGE:		20040922

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PHARMION CORP
		CENTRAL INDEX KEY:			0001203866
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50447
		FILM NUMBER:		041041152

	BUSINESS ADDRESS:	
		STREET 1:		2525 28TH STREET
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301
		BUSINESS PHONE:		720 564 9100
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d18609e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">





<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
PURSUANT TO SECTION 13 OR 15(d) OF THE<BR>
SECURITIES EXCHANGE ACT OF 1934</B>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="36%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="63%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date of Report (Date of earliest event reported)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>September&nbsp;22, 2004</B></TD>
</TR>

<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade>&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 24pt"><B>Pharmion Corporation</B>
<HR size="1" noshade width="100%" align="center">
<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-50447</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>84-1521333</B></TD>
</TR>

<TR style="font-size: 1px">
    <TD align="center" valign="top"><HR size="1" noshade>&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><HR size="1" noshade>&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><HR size="1" noshade>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction<BR>
of incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission File<BR>
Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(IRS Employer<BR>
Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">2525 28th Street, Boulder, Colorado
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">80301</TD>
</TR>

<TR style="font-size: 1px">
    <TD align="center" valign="top"><HR size="1" noshade>&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><HR size="1" noshade>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(Address of principal executive offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="38%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="61%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Registrant&#146;s telephone number, including area code
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">720-564-9100</TD>
</TR>

<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade>&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P>&nbsp;

<DIV align="center" style="font-size: 10pt"><HR size="1" noshade width="100%" align="center">
(Former name or former address if changed since last report)</DIV>


<P align="left" style="font-size: 10pt">Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following
provisions:


<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
        <TD width="3%">&nbsp;</TD>
        <TD width="2%">&nbsp;</TD>
        <TD width="95%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD valign="top"><FONT size="2"><font face="Wingdings">&#111;</font></FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">
Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)</FONT></TD>
</TR>

<TR valign="bottom">
        <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
        <TD valign="top"><FONT size="2"><font face="Wingdings">&#111;</font></FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)</FONT></TD>
</TR>

<TR valign="bottom">
        <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
        <TD valign="top"><FONT size="2"><font face="Wingdings">&#111;</font></FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR>

<TR valign="bottom">
        <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
        <TD valign="top"><FONT size="2"><font face="Wingdings">&#111;</font></FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR>
</TABLE>
</CENTER>


<P>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">








<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P>
<TABLE width="100%" border="0" cellpadding="2" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="1%"></TD>
    <TD width="99%"></TD>
</TR>
<TR valign="top">
    <TD nowrap><B><U>Item</U> 2.02.</B>&nbsp;</TD>
    <TD><B>Disclosure of Results of Operations and Financial Condition</B></TD>
</TR>
</TABLE>



<P align="left" style="margin-left:9%; font-size: 10pt">On September&nbsp;21, 2004, the
Pharmion Corporation issued a
press release announcing the
EMEA acceptance of the
Company&#146;s Marketing
Authorization Application for
Vidaza. A copy of the press
release is attached as
Exhibit&nbsp;99.1 to this Current
Report on Form 8-K. The
information in this Form 8-K
and the exhibit attached
hereto shall not be deemed
&#147;filed&#148; for purposes of
Section&nbsp;18 of the Securities
Exchange Act of 1934 (the
&#147;Exchange Act&#148;) or otherwise
subject to the liabilities of
that section, nor shall it be
deemed incorporated by
reference in any filing under
the Securities Act of 1933 or
the Exchange Act, except as
shall be expressly set forth
by specific reference in such
filing.


<P>
<TABLE width="100%" border="0" cellpadding="2" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="1%"></TD>
    <TD width="99%"></TD>
</TR>
<TR valign="top">
    <TD nowrap><B><U>Item</U> 9.01.</B>&nbsp;</TD>
    <TD><B>Financial Statements, Pro Forma Financial Information and Exhibits</B></TD>
</TR>
</TABLE>



<P align="left" style="margin-left:9%; font-size: 10pt">(c) Exhibit&nbsp;99.1 &#151; Press Release dated September&nbsp;21, 2004.<BR>
&nbsp;<BR>
This exhibit is furnished pursuant to Item&nbsp;9.01 and shall not be
deemed to be &#147;filed.&#148;


<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top">&nbsp;</TD>
    <TD colspan="3">PHARMION CORPORATION<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>Date: 9-22-04&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000"><B>/s/ Erle T. Mast</B>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">Erle T. Mast&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="center" style="font-size: 10pt"><B>EXHIBIT INDEX</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="91%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center"><B>Exhibit No.</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left"><B>Description</B><HR size="1" noshade></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release dated September&nbsp;21, 2004 announcing EMEA
acceptance of the Company&#146;s Marketing Authorization
Application for Vidaza.</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>




<P align="center" style="font-size: 10pt">3
</DIV>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d18609exv99w1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="right" style="font-size: 10pt"><B>EXHIBIT 99.1</B>



<P align="left" style="font-size: 10pt"><B>FOR IMMEDIATE RELEASE</B>



<P align="left" style="font-size: 10pt">Contact:<BR>
Breanna Burkart/Anna Sussman<BR>
Directors, Investor Relations and Corporate Communications<BR>
Pharmion Corporation<BR>
720-564-9150


<P align="center" style="font-size: 12pt"><B>EMEA Accepts Pharmion&#146;s Marketing Authorization Application<BR>
for Vidaza<SUP>TM</SUP> (azacitidine for injectable suspension) for Review</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BOULDER, Colo., Sept. 21, 2004 &#151; Pharmion Corporation (Nasdaq:PHRM)
announced today that the Agency for the Evaluation of Medicinal Products (EMEA)
has accepted for review the Company&#146;s Marketing Authorization Application (MAA)
for Vidaza for the treatment of Myelodysplastic Syndromes (MDS).

<P align="left" style="font-size: 10pt">&#147;We are pleased that the EMEA has accepted our application for Vidaza for
filing, and we look forward to working closely with the EMEA in the coming
months as we seek European regulatory approval for this treatment for this very
serious disease,&#148; said Judith A. Hemberger, executive vice president and chief
operating officer of Pharmion. &#147;Through our recent experience with the
approval and launch of Vidaza in the United States, we recognize the real
medical need that exists and hope to be able to provide a new treatment option
for European physicians and their patients with Myelodysplastic Syndromes.&#148;

<P align="left" style="font-size: 10pt">Vidaza has been granted Orphan Product Designation by the EMEA, which, if the
MAA is approved, entitles the drug to ten years of market exclusivity for MDS
in the European Union.

<P align="left" style="font-size: 10pt">Vidaza is the first drug approved in the United States for the treatment of
MDS. Vidaza received a full approval for all five subtypes of MDS from the
U.S. Food and Drug Administration on May&nbsp;19, 2004. These subtypes include:
refractory anemia (RA)&nbsp;or refractory anemia with ringed sideroblasts (RARS) (if
accompanied by neutropenia or thrombocytopenia or requiring transfusions),
refractory anemia with excess blasts (RAEB), refractory anemia with excess
blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).

<P align="left" style="font-size: 10pt">The U.S. and European submissions for Vidaza were based upon a National Cancer
Institute (NCI)&nbsp;sponsored Phase III study for the treatment of MDS, conducted
by Cancer and Leukemia Group B (CALGB), and two supportive Phase II CALGB
studies, which were also sponsored by the NCI.


<P align="center" style="font-size: 10pt">-more-



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="font-size: 10pt"><B>Pharmion&#146;s European Submission for Vidaza Accepted</B><BR>
Page Two

<P align="left" style="font-size: 10pt">About Vidaza (azacitidine)

<DIV align="left" style="font-size: 10pt">Azacitidine causes the death of rapidly dividing cells, including cancer cells
that are no longer responsive to normal growth control mechanisms. In addition
to this direct cytotoxic effect on abnormal cells in the bone marrow,
azacitidine is member of a class of drugs in development known as
&#147;hypomethylating&#148; or &#147;demethylating&#148; agents. Methylation of DNA is a major
mechanism regulating gene expression. Researchers have found that an increase
in methylation of DNA can result in blockage of the activity of genes that
regulate cell division and differentiation, known as &#147;suppressor genes.&#148; With
suppressor gene expression blocked, cell division becomes unregulated, allowing
or promoting cancer. In in-vitro studies, researchers have found that
azacitidine can reverse the methylation of DNA, which may restore normal
function to genes that are critical for differentiation and proliferation.
</DIV>

<P align="left" style="font-size: 10pt">About MDS:

<DIV align="left" style="font-size: 10pt">MDS is a bone marrow disorder characterized by the production of abnormally
functioning, immature blood cells. The highest prevalence of MDS is in patients
over 60&nbsp;years of age. Pharmion estimates there are approximately 30,000-40,000
new cases of MDS in the European Union each year. Survival rates range from six
months to six years for the different subtypes of MDS. MDS can result in death
from bleeding and infection in the majority of patients, and transformation to
acute myelogenous leukemia (AML)&nbsp;occurs in up to 40&nbsp;percent of patients. The
prognosis for patients transforming to AML is exceptionally poor.
</DIV>

<P align="left" style="font-size: 10pt">About Pharmion:

<DIV align="left" style="font-size: 10pt">Pharmion is a pharmaceutical company focused on acquiring, developing and
commercializing innovative products for the treatment of hematology and
oncology patients in the U.S., Europe and additional international markets. For
additional information about Pharmion, please visit the company&#146;s website at
www.pharmion.com.
</DIV>

<P align="left" style="font-size: 10pt"><B><I>Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: </I></B><I>This release contains forward-looking statements, which express the
current beliefs and expectations of management. Such statements are based on
current expectations and involve a number of known and unknown risks and
uncertainties that could cause Pharmion&#146;s future results, performance or
achievements to differ significantly from the results, performance or
achievements expressed or implied by such forward-looking statements. Important
factors that could cause or contribute to such differences include the status
and timing or regulatory approvals for Thalidomide Pharmion 50mg and Vidaza;
the impact of competition from other products under development by Pharmion&#146;s
competitors; the regulatory environment and changes in the health policies and
structure of various countries; acceptance and demand for new pharmaceutical
products and new therapies, uncertainties regarding market acceptance of
products newly launched, currently being sold or in development; Pharmion&#146;s
ability to successfully acquire rights to, develop and commercialize additional
pharmaceutical products; fluctuations in currency exchange rates, and other
factors that are discussed in Pharmion&#146;s filings with the U.S. Securities and
Exchange Commission. Forward-looking statements speak only as of the date on
which they are made, and Pharmion undertakes no obligation to update publicly
or revise any forward-looking statement, whether as a result of new
information, future developments or otherwise.</I>


<P align="center" style="font-size: 10pt">###




<P align="center" style="font-size: 10pt">&nbsp;
</DIV>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
